Literature DB >> 15173897

Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response.

Pierre Blier1, Gabriella Gobbi, Nasser Haddjeri, Luca Santarelli, Gina Mathew, René Hen.   

Abstract

Substance P (neurokinin-1 [NK1]) receptor antagonists appear to be effective antidepressant and anxiolytic agents, as indicated in 3 double-blind clinical trials. In laboratory animals, they promptly attenuate the responsiveness of serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE) neurons to agonists of their cell-body autoreceptors, as is the case for some antidepressant drugs that are currently in clinical use. Long-term, but not subacute, antagonism of NK1 receptors in rats increases 5-HT transmission in the hippocampus, a property common to all antidepressant treatments tested thus far. This enhancement seems to be mediated by a time-dependent increase in the firing rate of 5-HT neurons. Mice with the NK1 receptor deleted from their genetic code also have an increased firing rate of 5-HT neurons. Taken together, these observations strongly suggest that NK1 antagonists could become a new class of antidepressant and anxiolytic agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173897      PMCID: PMC400690     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  36 in total

1.  Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats.

Authors:  M J Millan; F Lejeune; G De Nanteuil; A Gobert
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

2.  Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments.

Authors:  N Haddjeri; S T Szabo; C de Montigny; P Blier
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

3.  Tryptophan depletion and depressive vulnerability.

Authors:  F A Moreno; A J Gelenberg; G R Heninger; R L Potter; K M McKnight; J Allen; A P Phillips; P L Delgado
Journal:  Biol Psychiatry       Date:  1999-08-15       Impact factor: 13.382

4.  Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

Authors:  M E Thase; A R Entsuah; R L Rudolph
Journal:  Br J Psychiatry       Date:  2001-03       Impact factor: 9.319

5.  Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment.

Authors:  J Dong; P Blier
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

6.  Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons.

Authors:  S E Gartside; E Hajós-Korcsok; E Bagdy; L G Hársing; T Sharp; M Hajós
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission.

Authors:  N Haddjeri; P Blier
Journal:  Biol Psychiatry       Date:  2001-08-01       Impact factor: 13.382

8.  Effect of neurokinin-I receptor antagonists on the function of 5-HT and noradrenaline neurons.

Authors:  N Haddjeri; P Blier
Journal:  Neuroreport       Date:  2000-04-27       Impact factor: 1.837

9.  Noradrenergic neurons expressing substance P receptor (NK1) in the locus coeruleus complex: a double immunofluorescence study in the rat.

Authors:  L W Chen; L C Wei; H L Liu; Z R Rao
Journal:  Brain Res       Date:  2000-08-04       Impact factor: 3.252

10.  Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function.

Authors:  L Santarelli; G Gobbi; P C Debs; E T Sibille; P Blier; R Hen; M J Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

View more
  14 in total

1.  Neurobiology of severe mental disorders: from cell to bedside 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal.

Authors:  Pierre-Paul Rompré; Emmanuel Stip; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2004-05       Impact factor: 6.186

2.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Investigation of the effect of homocysteinylation of substance P on its binding to the NK1 receptor using molecular dynamics simulation.

Authors:  Samira Davoudmanesh; Jafar Mohammadian Mosaabadi
Journal:  J Mol Model       Date:  2018-06-26       Impact factor: 1.810

4.  The Hypothalamic-Pituitary-Adrenal Axis and Serotonin Metabolism in Individual Brain Nuclei of Mice with Genetic Disruption of the NK1 Receptor Exposed to Acute Stress.

Authors:  Juraj Culman; Stephan Mühlenhoff; Annegret Blume; Jürgen Hedderich; Ulf Lützen; Stephen P Hunt; Nadia M J Rupniak; Yi Zhao
Journal:  Cell Mol Neurobiol       Date:  2018-06-15       Impact factor: 5.046

5.  Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release.

Authors:  Karl Ebner; Nicolas Singewald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-19       Impact factor: 3.000

6.  Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.

Authors:  Johanna M Jarcho; Natasha A Feier; Alberto Bert; Jennifer A Labus; Maunoo Lee; Jean Stains; Bahar Ebrat; Stephanie M Groman; Kirsten Tillisch; Arthur L Brody; Edythe D London; Mark A Mandelkern; Emeran A Mayer
Journal:  Pain       Date:  2013-03-05       Impact factor: 6.961

Review 7.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  The drugs don't work? antidepressants and the current and future pharmacological management of depression.

Authors:  Elizabeth Penn; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

9.  Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.

Authors:  Florence Loiseau; Claudine Le Bihan; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

10.  Synthesis of two potential NK1-receptor ligands using [1-11C]ethyl iodide and [1-11C]propyl iodide and initial PET-imaging.

Authors:  Stina Syvänen; Jonas Eriksson; Tove Genchel; Orjan Lindhe; Gunnar Antoni; Bengt Långström
Journal:  BMC Med Imaging       Date:  2007-07-30       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.